Results 281 to 290 of about 178,517 (322)
Some of the next articles are maybe not open access.

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.

Journal of Medicinal Chemistry
Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR signaling is a hallmark of many hematological malignancies, which makes it an ...
Daniel W Robbins   +32 more
semanticscholar   +1 more source

Bruton’s tyrosine kinase (Btk)—the critical tyrosine kinase in LPS signalling?

Immunology Letters, 2004
The discovery of the Toll-like receptors (TLRs) has revolutionised the field of innate immunity. One unresolved question regarding LPS signalling is whether there is a role for tyrosine kinases downstream of the LPS receptor. Studies in mice deficient in Bruton's tyrosine kinase have previously shown that they are defective in their responses to LPS ...
Luke A. J. O'Neill   +1 more
openaire   +3 more sources

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.

Science, 1993
The cytoplasmic tyrosine kinase, Bruton's tyrosine kinase (Btk, formerly bpk or atk), is crucial for B cell development. Loss of kinase activity results in the human immunodeficiency, X-linked agammaglobulinemia, characterized by a failure to produce B ...
D. Rawlings   +9 more
semanticscholar   +1 more source

Brutons Tyrosine Kinase as a New Therapeutic Target

Anti-Cancer Agents in Medicinal Chemistry, 2007
Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic ...
Heather E. Tibbles   +2 more
openaire   +3 more sources

Production of Monoclonal Antibodies to Bruton's Tyrosine Kinase

Hybridoma, 1995
Bruton's X-linked agammaglobulinemia is caused by mutations in a cytoplasmic protein tyrosine kinase termed Bruton's tyrosine kinase (BTK). The protein is expressed in all members of the B cell lineage and is critical for B cell development. The protein consists of several modules, including a pleckstrin homology domain and the Src homology domains SH1,
Donn M. Stewart   +2 more
openaire   +3 more sources

Bruton's Tyrosine Kinase (Btk)

2012
Bruton's tyrosine kinase (Btk) is a non-receptor tyrosine kinase belonging to the Tec family of kinases. Btk is critical for B-cell development, differentiation and signalling through the B-cell antigen receptor (BCR) as is evident by its genetic association to a human primary immunodeficiency disease known as X-linked Agammaglobulinemia (XLA).
Mark E. Schnute   +2 more
openaire   +2 more sources

Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors

Current Treatment Options in Oncology, 2020
There has been a significant shift in the management of B cell malignancies over the past decade. Initial strategies involving the use of systemic chemotherapies have been gradually replaced by more targeted therapies to improve survival and overall tolerability.
Mohammed Alomar   +3 more
openaire   +3 more sources

Bruton Tyrosine Kinase Degraders

American Journal of Clinical Oncology
Bruton tyrosine kinase (BTK) is a key enzyme involved in B-cell development and signaling, making it a crucial target in the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance—both intrinsic and acquired—poses a significant ...
Giorgi, Sabakhtarishvili   +3 more
openaire   +2 more sources

Genetic Variation in Bruton Tyrosine Kinase

2015
X-linked agammaglobulinemia (XLA) is a hereditary immunodeficiency caused by variations in the gene encoding for Bruton’s tyrosine kinase (BTK). Patients with XLA have decreased numbers of mature B cells, lack all immunoglobulin isotypes, and therefore have susceptibility to severe bacterial infections. XLA-causing variations are collected into BTKbase
Mauno Vihinen, Gerard C. P. Schaafsma
openaire   +2 more sources

Role of Bruton’s tyrosine kinase in macrophage apoptosis

Apoptosis, 2010
Macrophages and polymorphonuclear cells (PMNs) rapidly respond to microbial and immune inflammatory stimuli and die during these responses. We have shown earlier that many macrophage and PMN functions are compromised in x-linked immunodeficient (Xid) mice with functional deficiency in Bruton's tyrosine kinase (Btk).
Vineeta Bal   +7 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy